Shandong Weigao Blood Purification Products Co (603014) Fair Value & Analysis
Healthcare · CN · Market cap 14.3B CNY
Fair value as of: Aug 10, 2026
From 25 valuation models · updated today
Share price +3.0% over the past month.
A solid business, but screening 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥24.53). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (15 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 10, 2026.
How to read this chart
15‑month range ¥29.94 – ¥46.06 · fair‑value band ¥14.59 – ¥24.53 · the ¥34.19 price screens above the ¥19.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 10, 2026.
Analysis
Shandong Weigao Blood Purification Products Co (603014) currently trades at ¥34.19, while our model-based Fair Value estimate is ¥19.63, implying the stock looks roughly 42.6% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shandong Weigao Blood Purification Products Co generated revenue of 3.8B CNY at a net margin of 12.9%. Revenue grew 0.9% year over year. It earns a return on equity of 7.5%. Net debt stands at 349M CNY. Fundamentals as of Aug 10, 2026
Our scenario range runs from ¥14.59 (bear case) to ¥24.53 (bull case); at ¥34.19, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -43%, 603014 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (¥26.40) versus Dividend Discount (¥2.17). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 10, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China.
Full company description
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. The company was founded in 2004 and is based in Weihai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shandong Weigao Blood Purification Products Co reported revenue of ¥3.8B in FY2025 versus ¥2.9B in FY2021, a compound +6.7%/yr. Reported net income was ¥482M in FY2025, compounding +16.7%/yr from FY2021.
603014 screens 43% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 10, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Shandong Weigao Blood Purification Products Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shandong Weigao Blood Purification Products Co (603014) overvalued or undervalued?
What is the fair value of 603014?
What is the quality score of 603014?
What is the revenue of Shandong Weigao Blood Purification Products Co (603014)?
What is the net profit margin of 603014?
Does Shandong Weigao Blood Purification Products Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shandong Weigao Blood Purification Products Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.